These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18486728)

  • 1. Trastuzumab: possible publication bias.
    Metcalfe S; Burgess C; Laking G; Evans J; Wells S; Crausaz S
    Lancet; 2008 May; 371(9625):1646-8. PubMed ID: 18486728
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuation of trastuzumab beyond disease progression.
    Montemurro F; Faggiuolo R; Redana S; Donadio M; Minischetti M; Durando A; Vietti-Ramus G; Buosi R; Aglietta M
    J Clin Oncol; 2005 Apr; 23(12):2866-8; discussion 2868-9. PubMed ID: 15838006
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of publication bias related to results from trastuzumab study.
    Perez EA; Suman VJ
    Lancet; 2008 Aug; 372(9639):626-7. PubMed ID: 18722859
    [No Abstract]   [Full Text] [Related]  

  • 5. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 6. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 7. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab in breast cancer.
    Gounaris IG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular targeting therapy for breast neoplasms].
    Horiguchi J
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():415-21. PubMed ID: 17682186
    [No Abstract]   [Full Text] [Related]  

  • 11. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
    MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401
    [No Abstract]   [Full Text] [Related]  

  • 12. HERA crosses over.
    Joensuu H
    Lancet Oncol; 2011 Mar; 12(3):203-4. PubMed ID: 21354371
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab in the treatment of breast cancer.
    Hortobagyi GN
    N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
    [No Abstract]   [Full Text] [Related]  

  • 15. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuing trastuzumab beyond progression.
    Jahanzeb M
    J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 18. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab beyond disease progression: case closed?
    Valabrega G; Aglietta M; Montemurro F
    J Clin Oncol; 2009 Sep; 27(27):e121-2; author reply e124-5. PubMed ID: 19687323
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab.
    Perez EA; Palmieri FM; Brock SM
    Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.